Objective: Outcomes after radiotherapy for head and neck mucosal melanoma (MMHN). Methods: From 1974 to 2005, 17 patients with primary MMHN were treated with radiotherapy. Primary sites included nasal cavity, paranasal sinuses, and oral cavity or oropharynx. Thirteen patients received surgery and postoperative radiotherapy; 4 received definitive radiotherapy. Results: Local control was 79% at 1 and 5 years for 13 of 13 patients treated with surgery and postoperative radiotherapy compared with 1 of 4 patients treated with definitive radiotherapy. Three patients recurred in the neck; 13 patients developed distant metastases. Disease-free survival was 23% at 1 year and 18% at 5 years. Absolute and cause-specific survivals were identical (53% and 28% at 1 and 5 years). Conclusion: Locoregional control is relatively high after surgery and adjuvant radiotherapy, but most patients recur in distant sites; approximately one fourth of patients are cured at 5 years. Patients with unresectable tumor may be controlled with definitive radiotherapy.
M ucosal melanoma is a rare lesion comprising approximately 0.8% to1.3% of all melanomas. 1, 2 The head and neck accounts for over half (55%) of all mucosal melanomas, whereas other sites such as the anus and rectum (24%), female genitalia (18%), and the urinary system (3%) can also be involved. 1, 2 The incidence of mucosal melanoma of the head and neck (MMHN) varies by race. For example, in Japan, oral melanoma makes up 7.5% of all melanomas 3 ; however, cutaneous melanomas in this population are 10 times less frequent than in whites. 4 Although the incidence of cutaneous melanoma in the United States is increasing, the incidence of ocular and mucosal melanomas is thought to have remained stable. 2 MMHN has a relatively grim prognosis with a mean survival of approximately 17% at 5 years. 4 The most prevalent sites are the nasal cavity, 5, 6 oral cavity, [7] [8] [9] and paranasal sinuses, with 5-year survival rates of 31%, 12%, and 0%, respectively. 4 Primary mucosal melanomas of the pharynx, larynx, and esophagus are exceedingly rare. 4 The median age of patients with head and neck mucosal melanoma is approximately 60 years; however, some authors have reported patients as young as 3 months. 8 There is a slight male preponderance (1.3:1). 10 The most common presenting symptoms are nasal obstruction and epistaxis 11, 12 ; other symptoms may include otitis media, diplopia, and dysphagia. Melanosis is seen in the majority of lesions, 7, 13 leading some to treat histologically benign melanosis as a premalignant condition. 7, 14 Desmoplastic melanomas, which are amelanotic lesions associated with chronically sun-damaged skin, rarely arise in head and neck mucosal sites. 15, 16 Several risk factors have been proposed for MMHN including exposure to sunlight, human papillomavirus, 17 chronic irritants, and carcinogenic compounds. However, none of these risk factors has been substantiated. 4 Some authors have reported that vascular invasion, 10 margin status, 14, 18 the use of postoperative radiotherapy (RT), 6, 9 clinical stage at presentation, 10 melanosis, 10 primary tumor thickness, 6 gender, 6 and response to treatment 6 are significant prognostic factors. Although postoperative RT 9 and vascular invasion 10 have been shown to significantly impact the likelihood of local control, only age Ͼ65, 19 clinical stage at presentation, 6, 9, 10, 20 level of invasion, 10, 15 and melanotic macules 6 have been shown to significantly influence survival.
Diagnostic evaluation should include fiberoptic nasopharyngoscopy and computed tomography to evaluate the primary tumor and cervical lymph nodes, as well as a chest radiogram to screen for lung metastasis. A magnetic resonance imaging scan can also be helpful, especially with sinonasal tumors. Additional studies to detect distant metastasis include chest computed tomography, bone scan, and positron emission tomography. 21 Biopsies stain positive for S-100, vimentin, and HMB-45, and are negative for epithelial membrane antigen and cytokeratin.
There is no formal American Joint Committee on Cancer (AJCC) TNM staging system for MMHN. 22 Although some researchers have staged the lesions according to the AJCC staging criteria for the site of origin, 9, 20 most use a simplified staging system described by Ballantyne 23 in 1970: stage I, disease confined to the primary site; stage II, regional lymph node metastasis; and stage III, distant metastasis. At presentation, approximately 75% of patients have stage I disease, 18% have stage II disease, and 7% have stage III disease. 4 Oral cavity lesions often remain asymptomatic for longer periods and thus more often present with stage II disease compared with sinonasal lesions. 10 Surgery with clear margins is the preferred treatment modality, 11 although complete resection is sometimes not achievable because of tumor location, extent, and associated morbidity. Neck dissection is frequently performed for clinically positive nodes and/or oral cavity primary lesions. Although melanoma was once considered "radioresistant," adjuvant RT may increase the likelihood of local control and unresectable lesions may occasionally be controlled with definitive RT. Although many reports confirm that local failure is a harbinger of distant metastasis, 4,10,11,14 a survival benefit associated with adjuvant RT has not been demonstrated. This lack of survival benefit may be due to selection bias, because RT is more often reserved for patients with close or positive surgical margins, perineural invasion, regional metastasis, and large primary tumors. 9, 13, 24 Salvage after local failure is achieved in only a small subset of patients. 4 Several schools of thought have emerged concerning fractionation schedules. Hypofractionation may theoretically provide an increased likelihood of local control because of the shape of the melanoma cell survival curve. Practically, the treatment of large MMHN sites with hypofractionation is often not well tolerated. Hyperfractionation may be useful to reduce the risk of late complications, particularly to the visual apparatus of patients with melanomas of the nasal cavity and paranasal sinues. Otherwise, conventional once-daily fractionation is employed.
Effective systemic adjuvant therapy is still needed to reduce the high rate of distant failure. Because of the rarity of MMHN, data must be extrapolated from studies evaluating adjuvant therapy for cutaneous melanoma. 25 
PATIENTS AND METHODS
The records of 17 patients with MMHN who were treated with curative intent between 1974 and 2005 were reviewed as part of an institutional review board-approved outcomes study. Primary sites included the nasal cavity (13 patients), paranasal sinuses (2 patients), and oral cavity or oropharynx (2 patients). Eleven patients were male and 6 were female. The mean age was 64 years (range, 40 -82 years).
Patients were staged using the 2002 AJCC system according to the primary site. 26 Stage distribution was as follows: stage I, 1 patient; stage II, 4 patients; stage III, 2 patients; stage IVA, 7 patients; and stage IVB, 3 patients. Three patients presented with nodal disease, including both patients with oral cavity or oropharynx melanomas.
Thirteen patients were treated with surgery and postoperative RT and 4 patients received definitive RT (Table 1) . Four patients underwent neck dissection (3 unilateral; 1 bilateral), and 9 patients received RT to the neck including all 3 patients who presented with positive nodes.
RT doses ranged from 45 to 74.4 Gy (mean, 66.9 Gy; median 69.2 Gy). Ten patients were treated with twice-daily fractionation at 1.2 Gy per fraction with a minimum 6-hour interfraction interval, and the other 7 patients were treated with once-daily fractionation at 1.7 to 3 Gy per fraction. One patient (patient 6) received split-course RT; the remaining 16 patients were treated with continuous course RT. Another 
Statistical Analysis
All statistical computations were performed with SAS software. 27 The rates of disease control and survival were calculated using the Kaplan-Meier product limit method. 28 
RESULTS
Treatment outcomes are summarized in Table 1 . The following are the 1-and 5-year outcomes: local control, 79% and 79%; regional control, 82% and 82%; locoregional control, 63% and 63%; distant metastasis-free survival, 29% and 24%; and disease-free survival, 23% and 18%, respectively.
Absolute and cause-specific survival rates were identical (53% and 28% at 1 and 5 years, respectively). Of the 17 patients treated, all but 4 (29%) died of recurrent disease with survivals ranging from 4 months to 70 months (median, 9 months). Two patients died of intercurrent disease at 12.6 years. Two patients are alive at 7.2 years and 23 months, respectively; the former has remained continuously diseasefree, whereas the latter underwent resection of a solitary distant pancreatic metastasis.
Local control was achieved in 13 of 13 patients (100%) treated with surgery and postoperative RT compared with 1 of 4 patients (25%) treated with definitive RT. There was no significant difference in the local control for patients treated once versus twice daily.
Regional control for patients treated with RT to the neck was 89% at 2.5 years compared with no RT to the neck (75% at 1 and 5 years, P ϭ 0.5153). The 3 patients who presented with regional metastasis were treated with surgery, neck dissection, and postoperative RT. All 3 patients died within 6 months of starting RT.
One patient suffered severe mucositis (patient 13) and was the only patient treated with hypofractionation (Ն3 Gy per fraction). He required a reduction in the total RT dose to 45 Gy because of this complication. Two patients experienced severe late treatment complications including bilateral blindness (1 patient) and bilateral glaucoma with cataracts and macular degeneration (1 patient). Both patients were treated with once-daily fractionation.
DISCUSSION
In a meta-analysis of 937 patients treated before 1991, Manolidis and Donald 4 reported an overall 5-year survival of 17% for all treatment modalities combined, noting that patients with sinonasal tumors had a better chance of survival than those with oral cavity tumors. Recent series reflecting more contemporary techniques show slightly improved overall 5-year survival rates varying from 20% to 32%, 5, 6, 9, 20, 29, 30 with a few as high as 35% to 47% (Table 2) . 10, 14, 18 
Surgery
Currently, wide resection of MMHN is the preferred method of treatment, although complete resection may be difficult depending on the location and extent of the tumor. 22 The literature on prophylactic lymph node dissection for MMHN is sparse leaving the decision to the discretion of the surgeon. Sentinel lymph node biopsy (SLNB) for patients with head and neck cancer remains under investigation. Shoaib et al 31 recently reported the distribution of sentinel node biopsies for 52 patients with oral mucosal head and neck cancer. Of the 124 sentinel nodes that were harvested, 113 One patient with a right tonsillar fossa lesion underwent a negative SLNB and neck dissection and had no evidence of disease at 19 months. The other patient, with a left anterior nasal septum lesion, was found to have a metastasis in the SLN but not in the neck dissection that followed; the patient succumbed to distant metastasis at 3 months. The authors concluded that SLNB is a potentially efficient staging tool and warrants further investigation.
Radiotherapy
Although melanoma was once considered "radioresistant," adjuvant RT has repeatedly been shown to improve local control in the contemporary literature. Although adjuvant RT has not been shown to significantly improve survival, Kingdom et al 33 has reported a strong trend in improved survival with postoperative RT compared with surgery alone, and Lee et al 12 observed a relationship between local control (regardless of treatment modality) and improved survival. These findings are reinforced by Manolidis' meta-analysis that showed a 73% rate of distant metastasis associated with local failure compared with 52% in those who were locally controlled. 4
Postoperative Radiotherapy
In the largest series to date analyzing RT for MMHN, Krengli et al 6 recently reported 74 patients treated at 9 institutions in the Netherlands between 1972 and 2002. Treatment consisted of surgery in 17 (23.0%) patients, surgery and RT in 42 (56.8%) patients, RT alone in 11 (14.9%) patients, and chemoimmunotherapy in 4 (5.4%) patients. With a median follow-up of 20 months, local control was significantly better at 3 years after surgery and RT (71%) compared with surgery alone (57%). Disease-specific survival was 47% at 5 years. Postoperative RT was shown to be a favorable prognostic factor in a univariate analysis, but was not significant in the multivariate analysis. Although, postoperative RT was found to improve both local control and locoregional control, it had no effect on overall or disease-free survival.
Temam et al 9 reviewed 69 patients with MMHN treated at the Institut Gustave-Roussy (Villejuif, France) between 1979 and 1997. Thirty patients underwent surgery alone and 39 received surgery and postoperative RT. Patients who received postoperative RT were more likely to have T3-T4 tumors (44% vs. 17%) and positive cervical nodes (33% vs. 13%) compared with those treated with surgery alone. With a mean follow-up of 3.8 years, local control was significantly better after surgery and postoperative RT compared with surgery alone (62% vs. 26%, respectively). Multivariate analysis revealed that postoperative RT was associated with better local control, independent of the primary tumor stage.
Definitive Radiotherapy
Definitive RT has been used to treat MMHN that are incompletely resectable and/or situations where resection would result in a severe functional or cosmetic deficit. Some authors favor definitive RT because of the propensity for MMHN to disseminate regardless of treatment modality. Although it remains the standard of care in some centers, 34 it is uncommonly used in the United States.
Gilligan et al 34 reviewed 28 patients with sinonasal mucosal melanoma treated with definitive RT at the Christie Hospital (Manchester, UK). RT doses varied from 50 to 55 Gy in 15 or 16 fractions over 20 to 21 days. Initial complete regression was observed in 79% of patients; 61% were locally controlled and the 5-year survival rate was 17.9%. No patient developed a radiation necrosis. The authors concluded that MMHN has a low likelihood of cure, irrespective of treatment modality, and the aim of treatment should be to achieve local control with minimal cosmetic and functional disability.
Shibuya et al 29 reviewed 28 patients with oral MMHN who were treated at the Tokyo Medical and Dental University (Japan) from 1963 to 1988. Twenty-five of 28 patients were treated with definitive RT. Techniques included intraoral mold (72-120 Gy in 5-10 days), intraoral cone electron therapy (50 -108 Gy in 5-10 fractions over 20 -50 days), external beam RT (50 -76 Gy in 5-7 weeks), and interstitial brachytherapy (90 Gy with198 Au). Local control and overall 5-year survival rates were 79% and 25%, respectively. Eight patients developed a bone exposure or osteoradionecrosis from 5 months to 2 years after treatment. The authors concluded that their results were as good or better than those obtained with surgery and advocated definitive RT for localized oral cavity mucosal melanoma.
All 4 of the patients in our series treated with definitive RT had stage III or IV disease and failed either locally or regionally.
Radioresistance and Fractionation
Since the early radiobiologic studies of the 1930s, melanoma has been thought to be "radioresistant" and characterized by its broad shoulder on the cell survival curve. 35, 36 The RTOG 83-05 trial was designed to compare conventional and hypofractionationed schedules for the palliative treatment of cutaneous melanoma. 36 One hundred twenty-six patients were randomized and received 8 Gy per fraction in 4 fractions given once weekly or 2.5 Gy per fraction in 20 fractions given 5 days a week over 26 to 28 days. The study was closed prematurely when an interim statistical analysis suggested that further accrual would not reveal a significant difference between the complete or partial remission rates for the 2 arms. Complete and partial remission rates for the hypofractionated and conventional treatment arms were 24.2% versus 23.4% and 35.5% versus 34.4%, respectively. The authors concluded that fractionation for melanoma should be based on lesion location, life expectancy, convenience, and efficacy.
Owens et al 8 fractions. Of the 20 patients treated with surgery alone, 45% failed locoregionally and 50% developed distant metastases. The 5-year survival rate for this group was 45%. Of the 24 patients treated with surgery and postoperative RT (who generally had more extensive disease), 17% failed locally and 46% developed distant metastasis. The 5-year survival for this second group was 29%.
CONCLUSION
Mucosal melanoma of the head and neck has a poor prognosis with few long-term survivors. Surgery is the mainstay of treatment. Postoperative RT should be used in almost all cases because of the high risk of local recurrence after a complete resection, even for apparently localized tumors. The fractionation schedule varies with primary site. In general, conventional once-daily fractionation is employed unless parts of the visual apparatus are included in the RT volume. Hyperfractionation is employed in the latter instance to reduce the risk of late complications. 37, 38 Depending on the primary site, intensity modulated therapy (IMRT) may be useful to reduce the dose to radiosensitive structures such as the optic nerves and chiasm, parotid(s), and central nervous system. Elective treatment of the clinically negative neck with neck dissection or RT is indicated because of the high risk of subclinical disease. SLNB remains investigational and may be considered for selected patients. Definitive RT is employed for the subset of patients with incompletely resectable disease and may result in survival rates that are comparable to those obtained after surgery. However, it is likely that the probability of locoregional control is better after surgery and adjuvant RT. Additionally, patients treated with definitive RT may be at a higher risk for late complications such as damage to the visual apparatus. Because the risk of hematogenous dissemination is high, adjuvant systemic therapy, such as interferon, should be considered for essentially all patients.
